BR112017020053A2 - novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo - Google Patents

novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo

Info

Publication number
BR112017020053A2
BR112017020053A2 BR112017020053-8A BR112017020053A BR112017020053A2 BR 112017020053 A2 BR112017020053 A2 BR 112017020053A2 BR 112017020053 A BR112017020053 A BR 112017020053A BR 112017020053 A2 BR112017020053 A2 BR 112017020053A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
same
heterocyclic compound
preparing
new heterocyclic
Prior art date
Application number
BR112017020053-8A
Other languages
English (en)
Other versions
BR112017020053B1 (pt
Inventor
Seok Park Joon
Jung Yoon Youn
Jae Cho Min
Bin Lee Ho
Kyung Yoo Ja
Yong Lee Bong
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co., Ltd. filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of BR112017020053A2 publication Critical patent/BR112017020053A2/pt
Publication of BR112017020053B1 publication Critical patent/BR112017020053B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção se refere a um composto heterocíclico que apresenta uma nova estrutura que pode ser usada na prevenção ou tratamento de doenças causadas pela anormalidade em uma atividade de prs (prolil-trna sintetase), a um método para a preparação do mesmo e a uma composição farmacêutica compreendendo o mesmo.
BR112017020053-8A 2015-06-08 2016-06-07 Composto heterocíclico, composição farmacêutica que compreende o mesmo e uso do dito composto para prevenir ou tratar cânceres, doenças inflamatórias, doenças autoimunes ou fibrose BR112017020053B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150080722A KR102277538B1 (ko) 2015-06-08 2015-06-08 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR10-2015-0080722 2015-06-08
PCT/KR2016/005999 WO2016200116A1 (en) 2015-06-08 2016-06-07 Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
BR112017020053A2 true BR112017020053A2 (pt) 2018-06-05
BR112017020053B1 BR112017020053B1 (pt) 2023-01-31

Family

ID=57504227

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020053-8A BR112017020053B1 (pt) 2015-06-08 2016-06-07 Composto heterocíclico, composição farmacêutica que compreende o mesmo e uso do dito composto para prevenir ou tratar cânceres, doenças inflamatórias, doenças autoimunes ou fibrose

Country Status (21)

Country Link
US (1) US10011586B2 (pt)
EP (1) EP3303320B1 (pt)
JP (1) JP6605624B2 (pt)
KR (1) KR102277538B1 (pt)
CN (1) CN107428725B (pt)
AU (1) AU2016275210B2 (pt)
BR (1) BR112017020053B1 (pt)
CA (1) CA2977752C (pt)
ES (1) ES2769279T3 (pt)
HR (1) HRP20200104T8 (pt)
HU (1) HUE047537T2 (pt)
MA (1) MA42455B1 (pt)
MY (1) MY172656A (pt)
NZ (1) NZ735032A (pt)
PH (1) PH12017501735A1 (pt)
PL (1) PL3303320T3 (pt)
PT (1) PT3303320T (pt)
RS (1) RS59787B1 (pt)
RU (1) RU2675375C1 (pt)
SI (1) SI3303320T1 (pt)
WO (1) WO2016200116A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458923B (zh) 2014-06-23 2019-09-10 株式会社大熊制药 杂环化合物
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
KR20230092805A (ko) * 2021-12-17 2023-06-26 주식회사 대웅제약 (2R, 3S)-2-(3-(4,5-디클로로-1H-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형
WO2024080777A1 (ko) * 2022-10-12 2024-04-18 주식회사 대웅제약 신장염의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0709384T3 (da) * 1994-10-31 1999-08-23 Merck Patent Gmbh Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder
US9284297B2 (en) * 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
WO2010096170A2 (en) * 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
WO2013106702A1 (en) 2012-01-13 2013-07-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
CA2899363A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3060207A4 (en) * 2013-10-24 2017-04-12 Georgetown University Methods and compositions for treating cancer
CN106458923B (zh) * 2014-06-23 2019-09-10 株式会社大熊制药 杂环化合物

Also Published As

Publication number Publication date
CN107428725B (zh) 2020-01-03
MA42455B1 (fr) 2020-02-28
RS59787B1 (sr) 2020-02-28
CN107428725A (zh) 2017-12-01
NZ735032A (en) 2019-05-31
SI3303320T1 (sl) 2020-02-28
PH12017501735A1 (en) 2018-03-12
US10011586B2 (en) 2018-07-03
EP3303320A1 (en) 2018-04-11
EP3303320A4 (en) 2018-12-05
RU2675375C1 (ru) 2018-12-19
BR112017020053B1 (pt) 2023-01-31
KR102277538B1 (ko) 2021-07-14
MY172656A (en) 2019-12-09
KR20160144213A (ko) 2016-12-16
AU2016275210B2 (en) 2018-07-26
WO2016200116A1 (en) 2016-12-15
CA2977752C (en) 2020-03-31
AU2016275210A1 (en) 2017-09-21
JP2018515558A (ja) 2018-06-14
CA2977752A1 (en) 2016-12-15
US20180044322A1 (en) 2018-02-15
ES2769279T3 (es) 2020-06-25
EP3303320B1 (en) 2020-01-01
PL3303320T3 (pl) 2020-06-29
JP6605624B2 (ja) 2019-11-13
PT3303320T (pt) 2020-02-03
HRP20200104T8 (hr) 2021-02-19
HUE047537T2 (hu) 2020-05-28
HRP20200104T1 (hr) 2020-04-03

Similar Documents

Publication Publication Date Title
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112017004704A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
BR112016028476A2 (pt) compostos, composição, utilização de um composto, método para o combate dos fungos nocivos e sementes
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
DOP2016000253A (es) Nuevos compuestos
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
MX2016005437A (es) Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3 -carboxamida como inhibidores de glucosilceramida sintasa.
BR112017020053A2 (pt) novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: DE ACORDO COM COMUNICADO PUBLICADO NA RPI 2526 DE 04/06/2019 FICAM DEVOLVIDOS DE 11/06/2019 ATE 14/06/2019 OS PRAZOS VENCIDOS NAS DATAS DIVULGADAS DENTRO DO COMUNICADO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/06/2016, OBSERVADAS AS CONDICOES LEGAIS